Hepatitis C News

CHICAGO — During this year’s North American Society for Pediatric Gastroenterology, Hepatology & Nutrition annual meeting, Mercedes Martinez, MD, from the New York-Presbyterian Columbia University Irving Medical Center in New York, will co-host the Single Topic Symposium on Chronic Liver Disease Management for the Gastroenterologist.

In contrast to previous study results, hepatocellular carcinoma and decompensated cirrhosis rates were similar between patients coinfected with hepatitis C and HIV and those with hepatitis C alone, according to data.

The rates of hepatitis C infection at delivery among pregnant women in the U.S. increased between 2000 and 2015, especially among women with concomitant opioid use disorder, the prevalence of which also increased during that period.

Results from a real-world study of implementing hepatitis C testing into integrated care centers that deliver HIV services to people who inject drugs demonstrated superior infection awareness, testing and treatment compared with usual care.

WASHINGTON — An investigational vaccine failed to prevent chronic hepatitis C virus infection in a cohort of at-risk adults, according to results of a clinical trial presented at IDWeek.

With several highly effective, curative direct-acting antiviral options for patients with hepatitis C, the focus has changed from management of the viral infection to a march toward global elimination.

SAN ANTONIO — Healio will host its second Disruptive Innovators reception during the American College of Gastroenterology’s Annual Scientific Meeting (ACG 2019) on October 27, 2019, at the Grand Hyatt San Antonio.

The FDA has expanded the approval of Mavyret for a treatment duration of 8 weeks to include treatment-naive adults and children aged 12 years and older with chronic hepatitis C genotype 1 through 6 and compensated cirrhosis.

The introduction and success of direct-acting antivirals drove the Kidney Disease: Improving Global Outcomes work group to make major updates to its clinical practice guidelines regarding hepatitis C virus infection in chronic kidney disease, or CKD.

Results from a systematic review and meta-analysis revealed 13 risk factors for intrahepatic and extrahepatic cholangiocarcinoma, the most significant of which included biliary cysts and stones, cirrhosis, hepatitis B and hepatitis C.